In addition, AFP and DCP were gradually increased corresponding to BCLC stage (AFP: BCLC 0 or A versus BCLC C-D; P < 0.001, BCLC 0 or A versus BCLC B; P < 0.05) (DCP: BCLC 0 versus BCLC B; P < 0.01, BCLC 0 versus BCLC A or BCLC B versus BCLC C-D; P < 0.05) (Figure 2C) and HCC stage (AFP: stage I or II versus stage IVa-b; P < 0.0001, stage I or II versus stage III; P < 0.01) (DCP: stage I or II versus stage IVa-b; P < 0.0001, stage I versus stage III; P < 0.001, stage III versus stage IVa-b; P < 0.01, stage I versus stage II; P < 0.05) (Figure 2D). The gene discussed is ACE; the disease is hepatocellular carcinoma.